Skip to content

Celldex Therapeutics

US · CLDX #2630 by market cap Listed 1970
27.42 -0.54 -1.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 26.97 -3.54%
After-hours 27.40 -0.07%
44.8727.4227.422026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CLDX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -11.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 12.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 100.0% Better than 99%
Operating margin -18,599.8% Better than 0%
Net margin -16,748.0% Better than 1%
Return on equity -40.6% Better than 10%
Return on invested capital -40.4% Better than 8%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -32.1% Better than 16%
6-month return -10.8% Better than 39%
12-month return (ex latest month) 12.8% Better than 51%
Distance below 52-week high 39.3% Better than 29%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.5x Better than 94%
Debt to assets 0.4% Better than 96%
Interest coverage -87.0x Better than 5%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 90.9% Better than 74%
Upside to average target 145.0% Better than 90%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.89%
1M -9.48%
3M -31.35%
6M -11.26%
YTD +0.96%
1Y +9.37%
3Y +0.70%
5Y -36.20%

Key statistics

Price & volume

Prev close
27.96
Open
27.01
Day range
26.64 - 28.43
Avg price
27.45
Volume
1.72M
Turnover
47.10M
Amplitude
6.38%
52-week range
22.33 - 45.14

Valuation

P/E
-7.03
P/E (TTM)
-6.39
P/B
3.32
EPS
-3.90
Net profit
-306.33M
Net assets
649.49M

Share structure

Market cap
2.15B
Float cap
2.01B
Shares out
78.55M
Float shares
73.29M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 22% of range
22.33 45.14

39.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+9.17M net over the window

Short interest

Shares short
9.94M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Celldex Therapeutics (CLDX)?

Celldex Therapeutics last traded at 27.42. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Celldex Therapeutics's market cap?

About 2.15B.

What is the P/E ratio of Celldex Therapeutics?

The trailing twelve-month P/E is -6.39. The Valuation tab shows it against the stock's own five-year range.

Does Celldex Therapeutics pay a dividend?

Celldex Therapeutics does not currently pay a regular dividend.

Is Celldex Therapeutics a buy according to analysts?

The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 67.18, which implies 145.0% upside from the current price. This is not investment advice.

What is Celldex Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Celldex Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Celldex Therapeutics discussion 0 comments

Add a comment